English
简体中文
Total: £ 56.28
Published Date: 2025-11-24 | Pages: 94 | Tables: 86 | Medical Care
The global market for Latent Tuberculosis Infection (LTBI) Testing was estimated to be worth US$ 1550 million in 2024 and is forecast to a readjusted size of US$ 2228 million by 2031 with a CAGR of 5.4% during the forecast period 2025-2031.
The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.
Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc.
Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.
The detection industry of latent tuberculosis infection (LTBI) can be subdivided into several parts: tuberculin skin test (TST), interferon release test (IGRA), etc.
Globally, there are mainly Qiagen, Oxford Immunotec, Sanofi, etc.
Diagnosing and treating latent tuberculosis infection (LTBI) is an important strategy recognized by the World Health Organization to accelerate the decline of global tuberculosis and achieve the elimination of tuberculosis. Latent tuberculosis infection (LTBI) refers to the state of continuous immune response to the stimulation of Mycobacterium tuberculosis antigen in the absence of clinical evidence of active tuberculosis (TB). The diagnosis and treatment of long-term tuberculosis is very important for tuberculosis, especially for high-risk groups. Tuberculin skin tests (TST) and interferon release tests (IGRAs) were used to diagnose LTBI.
This report aims to provide a comprehensive presentation of the global market for Latent Tuberculosis Infection (LTBI) Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Latent Tuberculosis Infection (LTBI) Testing by region & country, by Type, and by Application.
The Latent Tuberculosis Infection (LTBI) Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Latent Tuberculosis Infection (LTBI) Testing.
Market Segmentation
By Company
Qiagen
Sanofi
Oxford Immunotec
Thermo Fisher Scientific
Par Sterile
Bio-Rad Laboratories
Segment by Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
Segment by Application
Hospitals and Clinics
Diagnostic Laboratories
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Latent Tuberculosis Infection (LTBI) Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Latent Tuberculosis Infection (LTBI) Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Latent Tuberculosis Infection (LTBI) Testing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Latent Tuberculosis Infection (LTBI) Testing Product Introduction
1.2 Global Latent Tuberculosis Infection (LTBI) Testing Market Size Forecast (2020-2031)
1.3 Latent Tuberculosis Infection (LTBI) Testing Market Trends & Drivers
1.3.1 Latent Tuberculosis Infection (LTBI) Testing Industry Trends
1.3.2 Latent Tuberculosis Infection (LTBI) Testing Market Drivers & Opportunity
1.3.3 Latent Tuberculosis Infection (LTBI) Testing Market Challenges
1.3.4 Latent Tuberculosis Infection (LTBI) Testing Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Latent Tuberculosis Infection (LTBI) Testing Players Revenue Ranking (2024)
2.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Company (2020-2025)
2.3 Key Companies Latent Tuberculosis Infection (LTBI) Testing Manufacturing Base Distribution and Headquarters
2.4 Key Companies Latent Tuberculosis Infection (LTBI) Testing Product Offered
2.5 Key Companies Time to Begin Mass Production of Latent Tuberculosis Infection (LTBI) Testing
2.6 Latent Tuberculosis Infection (LTBI) Testing Market Competitive Analysis
2.6.1 Latent Tuberculosis Infection (LTBI) Testing Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Latent Tuberculosis Infection (LTBI) Testing Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Latent Tuberculosis Infection (LTBI) Testing as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tuberculin Skin Test (TST)
3.1.2 Interferon Gamma Released Assay (IGRA)
3.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type
3.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value, by Type (2020-2031)
3.2.3 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals and Clinics
4.1.2 Diagnostic Laboratories
4.1.3 Others
4.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application
4.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value, by Application (2020-2031)
4.2.3 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region
5.1.1 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (2020-2025)
5.1.3 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (2026-2031)
5.1.4 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
5.2.2 North America Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
5.3.2 Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
5.4.2 Asia Pacific Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
5.5.2 South America Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
5.6.2 Middle East & Africa Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
6.3 United States
6.3.1 United States Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
6.3.2 United States Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
6.4.2 Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
6.5.2 China Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
6.5.3 China Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
6.6.2 Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
6.7.2 South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
6.8.2 Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020-2031
6.9.2 India Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
6.9.3 India Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Qiagen
7.1.1 Qiagen Profile
7.1.2 Qiagen Main Business
7.1.3 Qiagen Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
7.1.4 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) & (2020-2025)
7.1.5 Qiagen Recent Developments
7.2 Sanofi
7.2.1 Sanofi Profile
7.2.2 Sanofi Main Business
7.2.3 Sanofi Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
7.2.4 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) & (2020-2025)
7.2.5 Sanofi Recent Developments
7.3 Oxford Immunotec
7.3.1 Oxford Immunotec Profile
7.3.2 Oxford Immunotec Main Business
7.3.3 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
7.3.4 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) & (2020-2025)
7.3.5 Oxford Immunotec Recent Developments
7.4 Thermo Fisher Scientific
7.4.1 Thermo Fisher Scientific Profile
7.4.2 Thermo Fisher Scientific Main Business
7.4.3 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
7.4.4 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) & (2020-2025)
7.4.5 Thermo Fisher Scientific Recent Developments
7.5 Par Sterile
7.5.1 Par Sterile Profile
7.5.2 Par Sterile Main Business
7.5.3 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
7.5.4 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) & (2020-2025)
7.5.5 Par Sterile Recent Developments
7.6 Bio-Rad Laboratories
7.6.1 Bio-Rad Laboratories Profile
7.6.2 Bio-Rad Laboratories Main Business
7.6.3 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
7.6.4 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) & (2020-2025)
7.6.5 Bio-Rad Laboratories Recent Developments
8 Industry Chain Analysis
8.1 Latent Tuberculosis Infection (LTBI) Testing Industrial Chain
8.2 Latent Tuberculosis Infection (LTBI) Testing Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Latent Tuberculosis Infection (LTBI) Testing Sales Model
8.5.2 Sales Channel
8.5.3 Latent Tuberculosis Infection (LTBI) Testing Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Latent Tuberculosis Infection (LTBI) Testing Market Trends
Table 2. Latent Tuberculosis Infection (LTBI) Testing Market Drivers & Opportunity
Table 3. Latent Tuberculosis Infection (LTBI) Testing Market Challenges
Table 4. Latent Tuberculosis Infection (LTBI) Testing Market Restraints
Table 5. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Company (2020-2025)
Table 7. Key Companies Latent Tuberculosis Infection (LTBI) Testing Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Latent Tuberculosis Infection (LTBI) Testing Product Type
Table 9. Key Companies Time to Begin Mass Production of Latent Tuberculosis Infection (LTBI) Testing
Table 10. Global Latent Tuberculosis Infection (LTBI) Testing Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Latent Tuberculosis Infection (LTBI) Testing as of 2024)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 14. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (2020-2025) & (US$ Million)
Table 15. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (2026-2031) & (US$ Million)
Table 16. Global Latent Tuberculosis Infection (LTBI) Testing Sales Market Share in Value by Type (2020-2025)
Table 17. Global Latent Tuberculosis Infection (LTBI) Testing Sales Market Share in Value by Type (2026-2031)
Table 18. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 19. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (2020-2025) & (US$ Million)
Table 20. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (2026-2031) & (US$ Million)
Table 21. Global Latent Tuberculosis Infection (LTBI) Testing Sales Market Share in Value by Application (2020-2025)
Table 22. Global Latent Tuberculosis Infection (LTBI) Testing Sales Market Share in Value by Application (2026-2031)
Table 23. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 24. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (2020-2025) & (US$ Million)
Table 25. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (2026-2031) & (US$ Million)
Table 26. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (2020-2025) & (%)
Table 27. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (2026-2031) & (%)
Table 28. Key Countries/Regions Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 29. Key Countries/Regions Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2025) & (US$ Million)
Table 30. Key Countries/Regions Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2026-2031) & (US$ Million)
Table 31. Qiagen Basic Information List
Table 32. Qiagen Description and Business Overview
Table 33. Qiagen Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
Table 34. Revenue (US$ Million) in Latent Tuberculosis Infection (LTBI) Testing Business of Qiagen (2020-2025)
Table 35. Qiagen Recent Developments
Table 36. Sanofi Basic Information List
Table 37. Sanofi Description and Business Overview
Table 38. Sanofi Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
Table 39. Revenue (US$ Million) in Latent Tuberculosis Infection (LTBI) Testing Business of Sanofi (2020-2025)
Table 40. Sanofi Recent Developments
Table 41. Oxford Immunotec Basic Information List
Table 42. Oxford Immunotec Description and Business Overview
Table 43. Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
Table 44. Revenue (US$ Million) in Latent Tuberculosis Infection (LTBI) Testing Business of Oxford Immunotec (2020-2025)
Table 45. Oxford Immunotec Recent Developments
Table 46. Thermo Fisher Scientific Basic Information List
Table 47. Thermo Fisher Scientific Description and Business Overview
Table 48. Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
Table 49. Revenue (US$ Million) in Latent Tuberculosis Infection (LTBI) Testing Business of Thermo Fisher Scientific (2020-2025)
Table 50. Thermo Fisher Scientific Recent Developments
Table 51. Par Sterile Basic Information List
Table 52. Par Sterile Description and Business Overview
Table 53. Par Sterile Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
Table 54. Revenue (US$ Million) in Latent Tuberculosis Infection (LTBI) Testing Business of Par Sterile (2020-2025)
Table 55. Par Sterile Recent Developments
Table 56. Bio-Rad Laboratories Basic Information List
Table 57. Bio-Rad Laboratories Description and Business Overview
Table 58. Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Products, Services and Solutions
Table 59. Revenue (US$ Million) in Latent Tuberculosis Infection (LTBI) Testing Business of Bio-Rad Laboratories (2020-2025)
Table 60. Bio-Rad Laboratories Recent Developments
Table 61. Key Raw Materials Lists
Table 62. Raw Materials Key Suppliers Lists
Table 63. Latent Tuberculosis Infection (LTBI) Testing Downstream Customers
Table 64. Latent Tuberculosis Infection (LTBI) Testing Distributors List
Table 65. Research Programs/Design for This Report
Table 66. Key Data Information from Secondary Sources
Table 67. Key Data Information from Primary Sources
Table 68. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Latent Tuberculosis Infection (LTBI) Testing Product Picture
Figure 2. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value (2020-2031) & (US$ Million)
Figure 4. Latent Tuberculosis Infection (LTBI) Testing Report Years Considered
Figure 5. Global Latent Tuberculosis Infection (LTBI) Testing Players Revenue Ranking (2024) & (US$ Million)
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Latent Tuberculosis Infection (LTBI) Testing Revenue in 2024
Figure 7. Latent Tuberculosis Infection (LTBI) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 8. Tuberculin Skin Test (TST) Picture
Figure 9. Interferon Gamma Released Assay (IGRA) Picture
Figure 10. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 11. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Market Share by Type, 2024 & 2031
Figure 12. Product Picture of Hospitals and Clinics
Figure 13. Product Picture of Diagnostic Laboratories
Figure 14. Product Picture of Others
Figure 15. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 16. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Market Share by Application, 2024 & 2031
Figure 17. North America Latent Tuberculosis Infection (LTBI) Testing Sales Value (2020-2031) & (US$ Million)
Figure 18. North America Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (%), 2024 VS 2031
Figure 19. Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 20. Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (%), 2024 VS 2031
Figure 21. Asia Pacific Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 22. Asia Pacific Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (%), 2024 VS 2031
Figure 23. South America Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 24. South America Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (%), 2024 VS 2031
Figure 25. Middle East & Africa Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 26. Middle East & Africa Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (%), 2024 VS 2031
Figure 27. Key Countries/Regions Latent Tuberculosis Infection (LTBI) Testing Sales Value (%), (2020-2031)
Figure 28. United States Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 29. United States Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
Figure 30. United States Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (%), 2024 VS 2031
Figure 31. Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 32. Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
Figure 33. Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (%), 2024 VS 2031
Figure 34. China Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 35. China Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
Figure 36. China Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (%), 2024 VS 2031
Figure 37. Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 38. Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
Figure 39. Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (%), 2024 VS 2031
Figure 40. South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 41. South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
Figure 42. South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (%), 2024 VS 2031
Figure 43. Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 44. Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
Figure 45. Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (%), 2024 VS 2031
Figure 46. India Latent Tuberculosis Infection (LTBI) Testing Sales Value, (2020-2031) & (US$ Million)
Figure 47. India Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (%), 2024 VS 2031
Figure 48. India Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (%), 2024 VS 2031
Figure 49. Latent Tuberculosis Infection (LTBI) Testing Industrial Chain
Figure 50. Latent Tuberculosis Infection (LTBI) Testing Manufacturing Cost Structure
Figure 51. Channels of Distribution (Direct Sales, and Distribution)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
